



REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



To,

July 02, 2024

BSE Ltd.
Listing Compliance Department
P.J. Tower, Dalal Street,
Fort, Mumbai — 400 001

Sub: Intimation of the Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, July 08, 2024, inter alia to:

1. Consider and approve the proposal for fund raising through Qualified Institutional Placement (QIP):
 - (i) To evaluate and approve the proposal to raise funds up to Rs. 200,00,00,000/- (Rupees Two Hundred Crores Only) by way of issuance of equity shares, convertible securities, or other eligible instruments to Qualified Institutional Buyers (QIBs) to finance the acquisition of Good Manufacturing Practices (GMP) assets in the Active Pharmaceutical Ingredients (API) and Intermediates space, as well as the acquisition of technology, Intellectual Property (IP), including US Drug Master File (USDMF), Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP), tech packages, and other relevant assets.
 - (ii) To determine the quantum, terms, and conditions of the QIP, including but not limited to the pricing, timing, and other relevant aspects of the issuance.
 - (iii) To discuss and authorise the engagement of necessary intermediaries, including investment bankers, legal advisors, and other professionals for the QIP process.
2. Consider allotment of Bonus Shares to the Equity Shareholders of the Company as on record date.
3. Consider any other matter with the approval of the Board:

Any other matters necessary to effectively implement the fund-raising and acquisition process.

The Board would also consider convening an extra-ordinary general meeting/ postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal of fund raising, as required.

Further with reference to our letter dated June 25, 2024 with regards to Closure of Trading window for dealing in shares of the Company in accordance with the SEBI (Prohibition of Insider Trading), Regulations, 2015, the Trading Window for Company's securities is closed from July 01, 2024 and shall remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended 30th June, 2024.

Kindly take the above on record.

Thanking you,

Yours Sincerely,

For Remedium Lifecare Limited



Adarsh Munjal
Whole Time Director